Collectively, our data indicated that treatment with FGFR inhibitors, particularly FGFR4 inhibitors, may lead to EZH2 accumulation via activating non-canonical NF-kB signaling, whereas elevated EZH2 in HCC patients was associated with poor progression. Here, FGFR4 is linked to hepatocellular carcinoma.